NCT02676895View on ClinicalTrials.gov

A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

August 8, 2016

Primary Completion Date

March 10, 2017

Study Completion Date

March 10, 2017

Conditions
Shigella Sonnei Infection
Interventions
BIOLOGICAL

GVGH S. sonnei (1790GAHB) vaccine 25 μg

Two injections of the study vaccine were administered 28 days apart.

BIOLOGICAL

GVGH S. sonnei (1790GAHB) vaccine 100 μg

Two injections of the study vaccine were administered 28 days apart.

BIOLOGICAL

Menveo

One injection of Menveo was administered in subjects in the Control Group.

BIOLOGICAL

Boostrix

One injection of Boostrix was administered in subjects in the Control Group.

Trial Locations (1)

80108

GSK Investigational Site, Kilifi

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02676895 - A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults | Biotech Hunter | Biotech Hunter